Newsroom

DURHAM, N.C.--(BUSINESS WIRE)--FlexGen Power Systems, LLC. (“FlexGen”), un fornitore leader di sistemi di accumulo di energia a batteria e di software per la gestione energetica, oggi ha annunciato che la sua piattaforma di gestione dell'energia HybridOS è certificata ISO 9001:2015. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua or...

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to 15 intradermal (ID) injections per treatment visit can be simplified to a single subcutaneous (SC) injection per visit. During a Type C meeting with the U.S. Food and Drug Administration in May 2026, the Company d...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease program and broader platform technology, with incentives to expand the application of Sail's in vivo CAR-T platform across additional therapeutic targets over...

MAPLE GROVE, Minnesota--(BUSINESS WIRE)--VDyne Inc. (« VDyne »), société privée de dispositifs médicaux développant un système innovant de remplacement valvulaire tricuspide par cathétérisme (RVTC), a annoncé aujourd’hui le recrutement et le traitement du premier patient dans l’étude pivot TRIVITA US IDE du système TriNova™. Cette étude randomisée et contrôlée comparera directement le système TriNova™ au système RVTC Edwards EVOQUE™, déjà commercialisé. Le démarrage de l’essai TRIVITA (NCT07516...

NEW YORK--(BUSINESS WIRE)--Franklin BSP Realty Trust, Inc. (NYSE: FBRT) (“FBRT” or the “Company”) today announced financial results for the quarter ended June 30, 2026. During the second quarter, FBRT increased GAAP book value per share, generated distributable earnings that exceeded its quarterly dividend, continued repurchasing common stock and made further progress resolving legacy assets. Second Quarter 2026 Summary GAAP net income of $16.3 million or $0.12 per diluted common share Distribu...

NEW YORK--(BUSINESS WIRE)--Griffon Corporation (“Griffon” or the “Company”) (NYSE: GFF) today announced it will release the Company’s fiscal third quarter results on Wednesday, August 5, 2026, followed by a conference call at 8:30 AM ET. The call can be accessed by dialing 1-844-826-3035 (U.S. participants) or 1-412-317-5195 (International participants). Callers should ask to be connected to the Griffon Corporation teleconference or provide conference ID number 10210214. Participants are encour...

NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--Ingevity raises full year Adjusted EBITDA outlook following a solid start to the year...

MAPLE GROVE, Minn.--(BUSINESS WIRE)--VDyne Inc. (“VDyne”), società privata produttrice di dispositivi medici che sviluppa un sistema innovativo di sostituzione della valvola mitrale transcatetere (TTVR), oggi ha annunciato che il primo paziente è stato registrato e trattato nello studio pivotale TRIVITA US IDE del sistema TriNova™. Lo studio randomizzato e controllato metterà a confronto diretto TriNova con il sistema disponibile in commercio Edwards EVOQUE™ TTVR. L'avvio dello studio clinico T...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines, today announced the publication of positive results from the abdominoplasty clinical trial evaluating LTG-001 for the treatment of moderate-to-severe acute postoperative pain as an original research article in the New England Journal of Medicine (NEJM). LTG-001 is an investigational selective Nav1.8 inhibitor, part of a new cl...

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Sonos, Inc. (Nasdaq: SONO) today announced the appointment of Chris Shackelton to its Board of Directors, effective July 28, 2026. The appointment is the latest step in the evolution of the Sonos Board, which has recently added directors with targeted expertise in areas central to the company. As Sonos enters its next chapter, Mr. Shackelton adds the perspective of a long-term investor, with experience across strategy, financial markets, and capital alloc...